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Abstract 
Introduction 
Many women experience emotional distress, depression and anxiety after a diagnosis of 
breast cancer. Psychological stress and depression have been associated with hypothalamic-
pituitary-adrenal (HPA) axis dysregulation that may adversely affect immune system 
functioning and impact upon survival. This study investigated the effects of a lifestyle 
intervention on indices of psychological health status, HPA axis regulation and immune 
function in overweight women recovering from early-stage breast cancer treatment. 
Methods 
A total of 85 women treated for breast cancer 3 to 18 months previously were randomly 
allocated to a 6-month exercise and hypocaloric healthy eating program plus usual care or 
usual care alone (control group). Women in the intervention group received three supervised 
exercise sessions per week and individualized dietary advice, supplemented by weekly 
nutrition seminars. Depressive symptoms (Beck Depression Inventory version II: BDI-II), 
perceived stress (Perceived Stress Scale: PSS), salivary diurnal cortisol rhythms; 
inflammatory cytokines (IL-6 and Tumor necrosis factor-α), leukocyte phenotype counts, 
natural killer (NK) cell cytotoxicity and lymphocyte proliferation following mitogenic 
stimulation were assessed at baseline and 6-month follow up. 
Results 
Compared with the control group, the intervention group exhibited a reduction in depressive 
symptoms (adjusted mean difference, 95 % confidence intervals (95 % CI): −3.12, −1.03 to 
−5.26; P = 0.004) at the 6-month follow-up but no significant decrease in PSS scores (−2.07, 
−4.96 to 0.82; P = 0.16). The lifestyle intervention also had a significant impact on diurnal 
salivary cortisol rhythm compared with usual care alone, as evidenced by an increase in 
morning salivary cortisol at the 6-month follow-up (P <0.04), indicating a change in HPA 
axis regulation. Women in the control group had higher total leukocyte, neutrophil and 
lymphocyte counts in comparison to the intervention group at the 6-month follow-up (P 
≤0.05), whereas there was no difference in NK cell counts (P = 0.46), NK cell cytotoxicity (P 
= 0.85) or lymphocyte proliferation responses (P = 0.11) between the two groups. 
Conclusion 
Our results show that the lifestyle intervention resulted in a reduction in depressive symptoms 
and a normalisation of HPA axis regulation. Such changes could have important implications 
for long-term survival in women recovering from early-breast cancer treatment. 
Trial registration 
Current Controlled Trials: ISRCTN08045231. 
Introduction 
Many women experience emotional distress, depression and anxiety after a diagnosis of 
breast cancer, which can persist for prolonged periods, irrespective of the clinical treatment 
outcome [1,2]. Studies show that a quarter of breast cancer patients have clinically important 
levels of emotional distress up to 12 months after treatment [3] and almost 50 % of women 
experience depression and/or anxiety during this period [1]. Psychological stress and 
depression have been associated with hypothalamic-pituitary-adrenal (HPA) axis 
dysregulation in breast cancer survivors, including aberrations in diurnal cortisol rhythm 
[4,5], and elevated levels of the inflammatory cytokine interleukin-6 (IL-6) [6] that may 
impair immune system functioning [7] and adversely impact upon survival [8,9]. 
The importance of healthy lifestyle behaviours to prevent the adverse effects of weight gain 
after a breast cancer diagnosis is widely acknowledged and sustainable lifestyle change was 
recently identified as one of the key areas for future research [10]. Lifestyle interventions that 
incorporate exercise and healthy eating advice could also have an important role in 
modulating indices of psychological health status during the early recovery phase after breast 
cancer treatment. Physical inactivity and poor dietary habits are independently associated 
with depressive symptoms in breast cancer survivors [11,12], whereas evidence suggests that 
regular exercise [13] and positive dietary change [14] can improve depressive symptoms and 
psychological well-being. By improving psychological health status, lifestyle interventions 
have the potential to impact upon the HPA axis regulation and enhance immune function in 
women recovering from breast cancer treatment. This could improve long-term outcome, as 
restoration of immune function after treatment is predictive of survival [15,16]. 
We recently reported the results of a randomised controlled trial that investigated the effects 
of an exercise and hypocaloric healthy eating intervention on body weight and metabolic 
biomarkers associated with disease recurrence in women recovering from early stage breast 
cancer treatment [17]. Women in the intervention group experienced a wide range of health 
benefits, including reductions in central adiposity, dietary fat intake, total cholesterol and 
resting diastolic blood pressure and an improvement in cardiopulmonary fitness [17]. Here, in 
the same patient cohort, we report the effects of the lifestyle intervention on indices of 
psychological health status, HPA axis regulation and immune function. 
Methods 
Participant recruitment 
This study recruited 90 overweight women with a BMI > 25 kg/m2 who had completed 
surgery, chemotherapy and radiotherapy for early stage breast cancer (stage I-III) 3–18 
months previously. Biological samples were unavailable for five women in the sample 
population, leaving an evaluable sample size of N = 85. Patients receiving adjuvant endocrine 
treatments were eligible, and those yet to complete a one year course of adjuvant trastuzumab 
were also included, subject to acceptable cardiac function determined by a multi-gated 
acquisition (MUGA) scan and consultant approval. Exclusion criteria included concomitant 
HRT or oral contraceptives; metastatic or active loco-regional disease; physical or psychiatric 
impairment limiting physical mobility; severe nausea, anorexia or other conditions precluding 
participation in exercise, the consumption of alternative/ complementary diets or use of high 
dose antioxidant supplements; and those already engaged in regular exercise. Patients were 
recruited from the Cancer Clinical Trials Centre at Weston Park Hospital, Sheffield UK or 
through local cancer support services, the local media or word of mouth. Ethics approval was 
obtained from the South Sheffield Research Ethics Committee and all participants provided 
written informed consent prior to the first assessment visit. 
Sample size 
Change in body weight was chosen as the primary outcome variable for calculation of sample 
size [17]. Using the data of Utter et al. [18], we estimated that recruitment of 90 women (45 
in each group) would give us 90 % power to detect a clinically meaningful reduction in body 
weight between the groups at the two-sided α level of 0.05. In addition, using BDI data from 
our previous exercise trial [13], a sample size of 38 patients per group gave us 80 % power to 
detect a change in BDI of 6 points at the alpha level of 0.05. 
Randomisation and allocation concealment 
Following the assessment of outcome variables at baseline, patients were randomly allocated 
to one of two groups: (i) lifestyle intervention (N = 44), or (ii) control group (N = 41). The 
control group received a healthy eating booklet, Eat Well (Food Standards Agency, UK) 
which also included brief advice on keeping active. Minimisation was used to balance the 
potentially confounding variables of chemotherapy and treatment with tamoxifen, aromatase 
inhibitors or no hormone therapy. Randomisation was performed by an independent 
researcher at the Clinical Trials Research Unit, University of Leeds. The randomisation 
sequence was not disclosed until patients had completed their baseline assessments. 
Lifestyle intervention 
Details of the pragmatic lifestyle intervention were published previously [17]. Briefly, the 24-
week lifestyle intervention combined three supervised exercise sessions each week with an 
individually tailored hypocaloric healthy eating program. Exercise sessions (including 1–3 
women) comprised 30 min of aerobic exercise (65-85 % age-predicted maximum heart rate) 
using one or more of a treadmill, cross-trainer, cycle ergometer and/or rowing ergometer, 
followed by 10–15 min of muscle strengthening exercises using resistance bands, hand 
weights and stability balls. Each participant also received one-to-one individualized dietary 
advice and written information (‘Weight Loss On A Plate’, Scottish Dietetic Association). 
The written information included guidance on portion sizes for common foods in each food 
group and a healthy eating plan. The goal was to reduce the patient’s total daily calorie intake 
to 600 kcal below their calculated energy requirements, thereby inducing an estimated steady 
weight loss of up to 0.5 kg each week. Additional weekly small-group nutrition education 
seminars included topics such as dietary fat intake, hydration, achieving a healthy balanced 
diet and alcohol consumption. In the control group, contact with researchers was limited to 
assessment sessions. Participants in the control group were offered three exercise sessions at 
the university exercise research facility and general exercise and dietary advice after the final 
follow-up. 
Outcome measures 
Outcomes were assessed at baseline (pre-randomisation) and at 24 weeks post-randomisation 
in both groups. Questionnaire outcomes (depressive symptoms and perceived stress) were 
assessed by a trained technician who was blinded to the group allocation. Saliva and blood 
analytes were measured blindly by members of the research team. 
Depressive symptoms and perceived stress 
Depressive symptoms were assessed using the Beck Depression Inventory, Version II© (BDI-
II) [19], which has a range of 0–63, with each item being rated on a 4-point Likert-type scale 
ranging from 0–3. Perceived stress was assessed using the Perceived Stress Scale [20] (PSS). 
The scale was developed to measure the extent to which respondents appraise situations in 
their life to be stressful during the past month. The 14-item scale has a range of 0–56, with 
items being rated on a Likert-type scale ranging from 0–4, and with higher scores indicating 
higher levels of perceived stress. 
Saliva and blood analysis 
Saliva samples were collected using salivettes® (Sarstedt, Leicester, UK) containing a piece 
of absorbance gauze at 8 am, 12 noon, 5 pm and 9 pm over three consecutive days and stored 
at 4 °C until collection. Saliva samples from each daily time point were pooled and mixed, 
before being cleared by centrifugation at 300 g for 10 min and stored for later analysis. Blood 
(15–20 ml) was drawn from an antecubital vein between 8:00–10:00 am in the morning 
following a 12 hour overnight fast. Saliva samples for analysis of diurnal cortisol rhythms 
and serum samples for analysis of inflammatory cytokines (IL-6 and TNF-α) were stored at -
80 º C until analysis, with duplicate baseline and post-intervention samples analysed in the 
same batch. Analysis of lymphocyte phenotype and function (T cell/natural killer [NK] cell 
phenotyping, lymphocyte proliferation in response to phytohemagglutinin [PHA] stimulation 
and NK cell cytotoxicity) were commenced within two hours of blood collection and 
analysed in duplicate or triplicate. Full blood count analyses were undertaken in the 
Haematology Department of the Sheffield Teaching Hospitals NHS Foundation Trust UK. 
All other analyses were undertaken in the Biomedical Research Centre Laboratory at 
Sheffield Hallam University UK, as described below. 
HPA axis modulation 
Diurnal salivary cortisol concentrations were determined using a high sensitivity enzyme-
linked immunosorbent assay (ELISA) assay kit (Salimetrics, Newmarket, UK). The detection 
limit is 0.003 µg/dL and the intra- and interassay coefficients of variation were 3.5 % and 5.1 
%, respectively. Salivary cortisol typically shows a diurnal response, being higher in the 
morning and lower in the evening. Hence, the area under the diurnal salivary cortisol curve 
(AUC) was calculated using the trapezoidal rule. The inflammatory cytokines, IL-6 and TNF-
α, were measured using high-sensitivity ELISA kits (R&D Systems, Oxon, UK). The inter- 
and intra-assay precisions were 7.8 % and 7.4 %, respectively for IL-6 and 8.4 % and 5.3 %, 
respectively for TNF-α. The lower limits of detection were 0.039 ρg/mL and 0.106 ρg/mL, 
respectively. 
Lymphocyte phenotyping 
Absolute counts of helper/inducer (CD3+CD4+) and suppressor/cytotoxic (CD3+CD8+) T 
lymphocytes and NK cells (CD3−CD16+CD56+) were determined using a three-colour whole-
blood staining technique (TriTestTM BD Biosciences, Oxon, UK). Briefly, whole blood (100 
µl) was incubated for 30 min at 4 °C with 10 µl of TriTestTM solution (three-colour direct 
immunofluorescence reagent) in TruCountTM tubes containing a predefined number of 
lyophilized latex beads (BD Biosciences, Oxon, UK), before the erythrocytes were lysed and 
the sample analysed immediately using flow cytometry (FAC-Sort flow cytometer with 
CELLQuest Pro data acquisition and analysis software; BD Biosciences, Oxon, UK). 
NK cell cytotoxicity 
Details of the NK cell cytotoxicity assay have been published previously [21]. Briefly, K562 
cells (NK cell-sensitive human erythroleukemic cell line) were grown in RPMI 1640 (Gibco-
BRL, UK), supplemented with 100 µg/mL streptomycin, 100 U/mL penicillin and 10 % fetal 
bovine serum (complete RPMI: cRPMI), before being labelled with the green fluorescent 
3,3′-dioctadecyloxacarbocyanine perchlorate (DIOC18(3), Sigma-Aldrich Ltd., Dorset, UK) at 
a concentration of 3 mM in dimethyl sulfoxide (DMSO). Unfractionated peripheral blood 
mononuclear cells (PBMCs) were used as the effector cell population. Peripheral blood was 
diluted 1:1 with 0.9 % w/v NaCl and two volumes of the diluted sample were layered over 
one volume of Nycoprep 1.077 (Axis-Shield Diagnostics Ltd., Huntingdon, UK). The 
gradient mixture was centrifuged at 300 g for 30 min and the PBMCs harvested from the 
interface. PBMCs were then resuspended in cRPMI (5 x 106 cells/mL) prior to their inclusion 
as effector cells in the NK cell cytotoxicity assay. PBMC effector cells and DIOC18(3)-
labelled K562 target cells were mixed together at five effector:target (E:T) cell ratios: 50:1, 
25:1, 12.5:1, 6.25:1 and 3.12:1, mixed thoroughly, pelleted by centrifugation at 300 g for 1 
minute and incubated for 3 hours at 37 °C in 5 % CO2/95 % air in a humid environment. The 
DNA stain propidium iodide (PI; 10 µg/mL), used to label non-viable cells, was then added 
immediately prior to flow cytometry analysis for determination of the proportion of live and 
dead K562 target cells at each E:T cell ratio. 
Lymphocyte proliferation assay 
Lymphocyte proliferation was measured using bromodeoxyuridine (BrdU) incorporation 
during DNA synthesis [22] after stimulation with the non-specific mitogen PHA. PBMCs (50 
µl of a 5 x 106 cells/mL suspension in cRPMI) were added to the wells of a 96-well flat 
bottom tissue microtitre plate before mixing with 50 µl of PHA at concentrations of 0 µg/mL 
(culture medium only), 0.1, 0.5, 1.0 and 10 µg/mL in cRPMI (final volume of 100 µl per 
well). Cultures (in triplicate) were incubated at 37 °C with 5 % CO2 for 48 hours and 
proliferation was assessed using a colorimetric BrdU immunoassay (BrdU Cell Proliferation 
ELISA: Roche Diagnostics GmbH, Germany). The mean optical density of antigen 
stimulated cultures/mean optical density of medium-only cultures was determined for each 
culture treatment and recorded. 
Data analysis 
Intention-to-treat analysis was used to compare patients in the groups to which they were 
randomly assigned, with missing data being imputed using the SPSS linear interpolation 
procedure. Three women were lost to follow-up in each group. The Shapiro Wilk’s test was 
used to check the normality of the data prior to data analysis, with non-normally distributed 
variables being log-transformed to normality before analysis. Comparisons between the 
groups were analysed using analysis of covariance (ANCOVA), with baseline values used as 
the covariate. Repeated measures ANOVA was used to assess for changes from baseline 
within the groups. Unless otherwise stated, normally-distributed data are presented as means 
± SD and non-normally distributed data as medians (semi-interquartile range [SIQR]). 
Categorical data were analysed using the chi-squared test (χ2). Statistical significance 
throughout was taken at the two-sided 5 % level (p < 0.05). All data were analysed using 
SPSS v19.0 (IBM, Somers, USA). 
Results 
The two groups were generally well-matched at baseline for key demographic and 
anthropometric variables (Table 1). In addition, levels of depression and perceived stress 
were well-balanced across the two groups. Nearly all the women were white Caucasian and 
on average, were 7–9 months post-treatment. Compliance to the supervised exercise sessions 
was excellent, with women attending, on average 84 % (42-98 %) of the sessions that were 
offered to them. 
Table 1 Baseline characteristics of the two groups 
Characteristic Intervention Group (n = 
44) 
Control Group (n = 
41) 
Age, years 55.8 (10.0) 55.3 (8.8) 
Body mass, kg 78.1 (10.1) 82.9 (17.0) 
Body Mass Index, kg/m2 29.7 (3.5) 31.1 (5.7) 
Waist circumference, cm 91.1 (9.9) 94.5 (13.8) 
Waist:Hip ratio 0.82 (0.07) 0.83 (0.06) 
Months post treatment 9.0 (5.5) 7.1 (4.4) 
Lymphoedema, No. (%) 9 (20.4) 15 (36.6) 
Ethnicity   
         White, No. (%) 43 (98) 41 (100) 
Marital status   
         Married/cohabitating, No. (%) 29 (66) 29 (71) 
         Single/windowed/divorced, No. 
(%) 
15 (34) 12 (29) 
Smokers, No. (%) 3 (6.8) 1 (2.4) 
Hormone treatment  
         Chemotherapy, No. (%) 26 (59.1) 22 (53.7) 
         Radiotherapy, No. (%) 38 (86.4) 33 (80.5) 
         Tamoxifen, No. (%) 21 (47.7) 21 (51.2) 
         Arimidex, No. (%) 14 (31.8) 10 (24.4) 
         Herceptin, No. (%) 3 (6.8) 5 (12.2) 
Depressive symptoms were reduced in the intervention group in comparison with controls at 
the 6-month follow-up (P = 0.004). This was due to a greater reduction in BDI-II scores from 
baseline in the intervention group (P < 0.001) in comparison with the controls (P = 0.02; 
Table 2). A total of 15 (34 %) of participants in the intervention group were at least mildly 
depressed at baseline (BDI-II ≥14 [19]), in comparison with 2 participants (4.5 %) at the 6-
month follow-up, whereas in the control group the number of at least mildly depressed 
participants remained constant (22 %) throughout the study period (χ2 = 5.93; P = 0.02). In 
contrast, the reduction in PSS score in the intervention group versus controls at the 6-month 
follow-up was not significant (P = 0.16), despite a significant reduction from baseline PSS 
score (P < 0.001, Table 2). 
Table 2 BDI-II and PSS scores at baseline and 6 months in the lifestyle intervention and 
usual care control groups 
 Intervention Group  Control Group  
 Baseline Follow-up ∆ Baseline Follow-up ∆ 
BDI-II 11.3 (7.6) 5.1 (4.9) −6.1 (6.9)** 10.2 (5.5) 7.9 (6.0) −2.3 (5.8)* 
PSS 22.9 (7.2) 18.2 (7.7) −4.8 (7.9)** 21.5 (5.6) 19.5 (6.8) −1.9 (6.8) 
BDI-II: Beck Depression Inventory-II; PSS: Perceived Stress Scale; ∆: change from the 
baseline score; *P < 0.05; **P < 0.01 in comparison with baseline (within groups). 
A pronounced diurnal cortisol rhythm was evident at baseline in both groups, with highest 
levels being recorded in the morning sample and lowest values in the evening (Figure 1). 
Although a similar diurnal cortisol rhythm was apparent in both groups at the 6-month 
follow-up, an increase in diurnal salivary cortisol rhythm AUC was observed in the lifestyle 
intervention group in comparison with the controls (P = 0.03; Figure 2). This was attributable 
to a higher post-intervention morning salivary cortisol concentration (P = 0.03; Figure 1). In 
contrast, the lifestyle intervention had no effect on circulating levels of the inflammatory 
cytokines, IL-6 (P = 0.93) or TNF-α (P = 0.61; Table 2). 
Figure 1 Diurnal Salivary cortisol rhythm at baseline and 6-month follow-up. Values are 
medians with error bars representing SIQR. *P = 0.03 for AUC between groups. 
Figure 2 NK cell cytotoxicity and lymphocyte proliferation at baseline and 6-month 
follow-up. Top: NK cell cytotoxicity at different effector: target cell ratios. Values are 
medians, with error bars representing SIQR. Bottom: Lymphocyte proliferation responses. 
Values are means with error bars representing SEM. 
An increase in total leukocyte count in the controls in comparison with the intervention group 
was observed at the 6-month follow-up (P = 0.04; Table 3), attributable to an increase in 
lymphocyte count (P = 0.04) and neutrophil count (P = 0.05). The CD3+CD4+ and 
CD3+CD8+ T cell counts showed a different pattern of response between the two groups (P ≤ 
0.05; Table 3). However, the lifestyle intervention had no effect on CD4+:CD8+ T cell ratio 
(P = 0.87), NK cell count (P = 0.46), NK cell cytotoxicity (P = 0.85) or lymphocyte 
proliferation in response to PHA stimulation (P = 0.11; Table 3 and Figure 2). 
  
Table 3 Leukocyte counts and inflammatory cytokines at baseline and follow-up 
 Intervention group Control group P 
value 
 Baseline Follow-up Baseline Follow-up 
Leukocyte counts      
         Total leukocyte count 
(103 cells/µl) 
5.145 (1.417) 5.156 (1.337) 5.184 (1.237) 5.594 (1.370) 0.04 
         Neutrophil count (103 
cells/µl) 
3.014 (1.119) 2.958 (1.135) 3.131 (0.912) 3.377 (1.061) 0.05 
         Monoctye count (103 
cells/µl) 
0.400 (0.370, 
0.430) 
0.400 0.360, 
0.440 
0.400 (0.350, 
0.450) 
0.400 (0.350, 
0.450) 
0.63 
         Lymphocyte count 
(103 cells/µl) 
1.507 (0.414) 1.523 (0.389) 1.446 (0.497) 1.612 (0.449) 0.04 
         CD3+CD4+T cells 
(103cells/µl) 
0.748 (0.596, 
0.900) 
0.682 (0.605, 
0.759) 
0.659 (0.532, 
0.786) 
0.763 (0.648, 
0.878) 
0.02 
         CD3+CD8+ T cells 
(103cells/µl) 
0.474 (0.365, 
0.583) 
0.402 (0.334, 
0.470) 
0.360 (0.214, 
0.506) 
0.409 (0.322, 
0.496) 
0.05 
         CD4+:CD8+ ratio 1.62 (1.36, 
1.88) 
1.69 (1.40, 
1.98) 
1.93 (1.51, 
2.35) 
1.91 (1.49, 
2.33) 
0.87 
         NK cells (103 
cells/µl) 
0.200 (0.175, 
0.225) 
0.206 (0.177, 
0.235) 
0.176 (0.147, 
0.205) 
0.174 (0.144, 
0.292) 
0.46 
Inflammatory cytokines      
         IL-6 (ρg/mL) 1.599 (1.259, 
1.906) 
1.692 (1.377, 
2.007) 
1.755 (1.456, 
2.054) 
1.942 (1.602, 
2.282) 
0.93 
         TNF-α(ρg/mL) 0.889 (0.779, 
0.999) 
0.916 (0.767, 
1.065) 
1.058 (0.895, 
1.221) 
0.992 (0.870, 
1.114) 
0.61 
Data are presented as Means (SD) or Medians (SIQR). P value shown for between group 
comparisons. 
Discussion 
Although pragmatic lifestyle interventions could be important for helping to prevent the 
adverse effects of weight gain after breast cancer treatment [10], few studies have assessed 
the impact of combined exercise and healthy eating programs on psychological wellbeing and 
associated prognostic biomarkers in breast cancer survivors [23,24]. This is the first study to 
report the effects of a combined exercise and healthy eating intervention on psychological 
health status, indices of HPA axis regulation and immune function in overweight women 
during the early recovery phase (3–18 months) after stage I-III breast cancer treatment. There 
was excellent compliance to the exercise sessions (84 %) and low attrition, with only three 
participants from each group being lost to follow-up in this analysis of psychological and 
neuro-immunological variables. An improvement in depressive symptoms in the intervention 
group was not accompanied by a significant reduction in perceived stress. However, the 
lifestyle intervention also had a significant impact on diurnal salivary cortisol rhythm, as 
evidenced by an increase in morning salivary cortisol at the 6-month follow-up. 
At baseline, BDI-II depression scores in our patient cohort were consistent with previous 
studies of breast cancer survivors [2,11,25]. Furthermore, the reduction in mean BDI-II 
depression score from baseline in the intervention group was similar to that previously 
reported following exercise interventions [25]. Improvements in depression scores have also 
been observed after lifestyle interventions involving a dietary component to promote healthy 
eating and healthy body weight maintenance [26,27] but this has not been a consistent finding 
[23]. Using the criterion of 0.5 SD for our sample population at baseline [28], a reduction in 
BDI-II score of >3 points is clinically meaningful. Hence, the 6.1 point reduction from 
baseline and between group difference of >3 points at the 6-month follow-up suggests that 
women in the intervention group experienced a clinically important change in depressive 
symptoms. Depressive symptoms in women recovering from breast cancer treatment have 
been associated with fatigue, pain, sleep disturbances, low libido, poor financial status and 
social support, and a range of other psychological factors [2]. Physical inactivity and poor 
dietary habits have also been independently associated with depressive symptoms in breast 
cancer survivors [11,12]. 
Evidence suggests that lifestyle interventions, which include support for exercise and dietary 
behaviour change, may improve depressive symptoms by improving mood, enhancing self 
efficacy expectations, reducing intrusive thoughts about breast cancer and future 
morbidity/mortality and buffering self-concept perceptions [27,29]. Reductions in body 
weight and/or body fat and improvements in cardiopulmonary fitness (as observed in the 
intervention participants [17]) could also have a positive impact on depression scores [30,31]. 
In addition, biological mechanisms including the release of monoamine neurotransmitters 
(i.e. serotonin, dopamine and norepinephrine) and endorphins during exercise have been 
proposed to account for improvements in depressive symptoms in physically active 
individuals [32]. However, it is also important to be mindful of attention effects on 
depression symptoms, as an improvement in BDI-II score was previously reported in the 
attention control arm of a short-term exercise trial in a similar cohort of early-stage breast 
cancer patients [13]. The increased level of personal contact between the intervention group 
and researchers is a potential limitation of the present study which needs to be taken into 
consideration. In summary, continued research is necessary to understand the extent to which 
such factors influenced the improvement in depressive symptoms in the present study and the 
impact of changes on long-term prognosis. 
Although the intervention group also exhibited a significant reduction in PSS scores from 
baseline levels, the smaller difference between groups at the 6-month follow-up was not 
significant. PSS scores in our patient cohort at baseline were comparable to those reported 
previously for breast cancer survivors [33-37]. However, the lack of effect on this outcome 
measure contrasts with previously reported reductions (in the range of 4–9 points) following 
stress management and yoga interventions in early-stage breast cancer patients [33-36]. A 
large proportion of breast cancer survivors are reported to use complementary therapies 
(including exercise) to manage stress [38], but only one previous study has reported 
reductions in PSS scale scores following exercise training [37]. The reduction after a 10-week 
programme of aerobic and resistance exercise in this study was only marginally greater than 
the non-significant difference between groups in our patient cohort at the 6-month follow-up. 
Hence, the lack of significant effect for perceived stress in the present study may be a 
reflection of low statistical power for this outcome. 
The intervention had a significant impact on HPA axis regulation, as evidenced by an 
increase in diurnal salivary cortisol rhythm at the 6-month follow-up. This was attributable to 
a higher morning salivary cortisol concentration. Cortisol levels follow a strong circadian 
rhythm in healthy adults, with the highest levels being evident in the morning after 
awakening and the nadir occurring at around midnight [39]. A pronounced diurnal cortisol 
rhythm was apparent at baseline in our patient cohort, and this is consistent with previous 
studies of non-metastatic breast cancer patients and survivors [4,5]. However, this is the first 
study to report a ‘steepening’ of diurnal cortisol rhythm following a lifestyle intervention in 
breast cancer patients in the early recovery phase after treatment. The implications of this are 
difficult to define but ‘flatter’ diurnal cortisol rhythms (blunted morning and/or elevated 
evening levels) have been associated with depressive symptoms, poor sleep quality and 
persistent fatigue after breast cancer treatment [5,40]. Hence, the intervention may have 
influenced morning cortisol levels via its positive impact on one or all of these factors, or via 
its impact on other factors not monitored in this study. Interestingly, an increase in morning 
cortisol level, accompanied by improvements in depressive symptoms and psychological 
stress, was reported after an 8-week stress reduction programme involving yoga, meditation 
and group discussions in breast cancer patients [33]. This was interpreted as evidence that the 
intervention resulted in a ‘normalisation’ of the cortisol response. In a similar way, our results 
may indicate a modest improvement in HPA axis regulation in the intervention group but 
further research is needed to confirm this and delineate the precise determinants of HPA axis 
modulation. 
Circulating levels of the inflammatory cytokines IL-6 and TNF-α have also been used as 
evidence of aberrant HPA axis regulation in breast cancer patients and other populations 
[6,7,9]. Depression and psychological stress are characterised by elevated levels of IL-6 and 
TNF-α, [6,41] and IL-6 stimulates cortisol secretion by adrenocortical cells [42]. However, in 
the present study, levels of these inflammatory cytokines were unchanged at the 6-month 
follow-up, and this is consistent with previous lifestyle intervention studies involving breast 
cancer survivors [23,24]. Elevated levels of these inflammatory cytokines have more 
generally been associated with severe and/or chronic depression and more marked HPA axis 
dysregulation in previous studies [6,9]. The pronounced diurnal cortisol rhythm at baseline in 
our patient cohort, coupled with evidence of mild depressive symptoms, suggests a more 
modest disruption of HPA axis regulation, which probably explains why the intervention had 
no effect on these inflammatory cytokines. 
This is also consistent with our results for immune function. Previous studies show that high 
levels of stress and depression, coupled with the persistent activation of the HPA axis, 
impairs immune responses and potentially contributes to the development and progression of 
cancer (reviewed by Reiche et al. [7]). However, indices of immune function (lymphocyte 
proliferation and NK cell cytotoxicity) were unchanged from baseline levels in the present 
study. Furthermore, the different pattern of response in CD3+CD4+ and CD3+CD8+ T cell 
counts is difficult to interpret, as baseline values were higher in the intervention group. 
Nevertheless, an increase in total leukocyte count, attributable to an increase in lymphocyte 
and neutrophil counts, was observed in the controls. The clinical implications of the latter are 
unknown but surgically-treated early-stage breast cancer patients who experienced disease 
recurrence exhibited higher lymphocyte and neutrophil counts relative to disease-free patients 
in the 17 months prior to recurrence detection [8]. This contrasts with earlier evidence of an 
association between low lymphocyte counts and breast cancer recurrence [43]. Although 
changes in circulating leukocyte counts during recovery from cancer treatment may be 
indicative of specific and/or non-specific immune reactions to sub-clinical disease [8,43], the 
clinical significance of such changes in our patient cohort is difficult to interpret without the 
longer-term follow-up of clinical end-points such as disease-free interval and mortality. 
Conclusions 
In conclusion, this study shows for the first time that an improvement in depressive 
symptoms resulting from supervised exercise and healthy eating advice in the early recovery 
phase, 3–18 months, after breast cancer treatment is accompanied by a significant change in 
diurnal salivary cortisol rhythm. The increase in morning salivary cortisol at the 6-month 
follow-up suggests a ‘normalisation’ of HPA axis regulation, which may be linked to the 
improvement in psychological health status. The precise determinants and clinical 
significance of these changes warrants further investigation. 
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